San Diego-based biopharmaceutical company Celladon Corp has postponed its IPO, Fortune reported. No reason was given for the delay. The company had planned to trade the stock on the NASDAQ under the ticker symbol “CLDN” on November 14, 2013. J.P. Morgan and Barclays were serving as lead underwriters. Celladon is backed by MPM Capital, LSP Life Sciences Partners, Pfizer Venture Investors, Lundbeckfond Ventures, Novartis Venture Funds, Tekla Capital Management, GBS Venture Partners and Enterprise Partners Venture Capital.